A Phase 3 interventional study of VEGF Trap-Eye (BAY86-5321) and No Drug in Myopia, Pathological, sponsored by Bayer. Completed at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-05.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to choroidal neovascularization secondary to pathologic myopia. This will be a placebo-controlled trial. 3 out of 4 patients will receive an injection of VEGF Trap-Eye into the affected eye (and repeated injections if required), and 1 out of 4 patients will receive a sham injection requiring no needle stick, but making the patient unaware of whether or not he received active treatment.
Outcome of the two treatment groups will be compared after 24 weeks. From week 24, sham patients may receive active treatment.
Total duration of the study will be 48 weeks.
71 studies on the registry are indexed under Myopia, Degenerative; 20 are open to participants now.
This study's enrollment of 122 is close to the median of 122 across 57 interventional studies indexed under Myopia, Degenerative.
Browse Myopia, Degenerative studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In the study eye:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: VEGF Trap-Eye (BAY86-5321)
Procedure: No Drug
1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried Forward (LOCF)
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning.
Time frame: Baseline, Week 24
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS at Week 24 Using the LOCF Approach
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 24
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS From Baseline to Week 24 - Observed Cases
Data as observed at visit, no carrying forward from latest observation if missing data at later time points. Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning.
Time frame: Baseline, Week 24
Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 24 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 24
Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 24 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 24
Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 48 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 48
Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 48 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 48
Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 48 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 48
Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 24 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 24
Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 24 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 24
Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 24 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 24
Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 48 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 48
Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 48 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 48
Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 48 - LOCF
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: Baseline, Week 48
Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 24 - LOCF
A negative number indicates improvement (reduced thickness).
Time frame: Baseline, Week 24
Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 48 - LOCF
A negative number indicates improvement (reduced thickness).
Time frame: Baseline, Week 48
Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 24 - LOCF
CNV area values measured in square millimeters, each disc area is equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes
Time frame: Baseline, Week 24
Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 48 - LOCF
CNV area values measured in square millimeters, each disc area is equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes
Time frame: Baseline, Week 48
Mean Change in European Five-dimensional Health Scale (EQ-5D) Score From Baseline to Week 24 - LOCF
EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).
Time frame: Baseline, Week 24
Mean Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 24 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.
Time frame: Baseline, Week 24
Percentage of Participants Who Were Withdrawn From Study Drug During the First 24 Weeks
Time frame: Baseline, Week 24
Mean Change in Area of Leakage From Baseline at Week 24 - LOCF
A negative change from baseline indicates improvement, ie, less leakage.
Time frame: Baseline, Week 24
The study was conducted at 20 study centers in 5 countries. Recruitment period: 17 Dec 2010 - 28 Feb 2013.
| Milestone | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Started | 91 | 31 |
| Participants received treatment | 91 | 31 |
| Fulfilled requirements of fas population | 90 | 31 |
| Completed 24 weeks treatment | 83 | 25 |
| Completed 48 weeks treatment | 78 | 24 |
| Completed | 85 | 31 |
| Not completed | 6 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 |
| Withdrew: Adverse event | 1 | 0 |
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning.
| Letters correctly read | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried Forward (LOCF) | 12.1 ± 8.3 | -2.0 ± 9.7 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS at Week 24 Using the LOCF Approach | 38.9 | 9.7 |
Data as observed at visit, no carrying forward from latest observation if missing data at later time points. Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning.
| Letters correctly read | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS From Baseline to Week 24 - Observed Cases | 12.0 ± 8.4 | -0.8 ± 9.3 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 24 - LOCF | 63.3 | 12.9 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 24 - LOCF | 83.3 | 19.4 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 48 - LOCF | 50.0 | 29.0 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 48 - LOCF | 68.9 | 41.9 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 48 - LOCF | 87.8 | 45.2 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 24 - LOCF | 0 | 6.5 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 24 - LOCF | 0 | 25.8 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 24 - LOCF | 3.3 | 35.5 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 48 - LOCF | 1.1 | 6.5 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 48 - LOCF | 1.1 | 22.6 |
Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 48 - LOCF | 3.3 | 29.0 |
A negative number indicates improvement (reduced thickness).
| microns | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 24 - LOCF | -79.1 ± 83.7 | -4.2 ± 127.4 |
A negative number indicates improvement (reduced thickness).
| microns | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 48 - LOCF | -83.1 ± 85.5 | -56.7 ± 119.0 |
CNV area values measured in square millimeters, each disc area is equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes
| Disc areas | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 24 - LOCF | -0.2233 ± 0.3195 | 0.3007 ± 0.4383 |
CNV area values measured in square millimeters, each disc area is equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes
| Disc areas | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 48 - LOCF | -0.1995 ± 0.4281 | -0.0111 ± 0.4031 |
EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).
| Scores on a scale | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Mean Change in European Five-dimensional Health Scale (EQ-5D) Score From Baseline to Week 24 - LOCF | 0.0187 ± 0.1749 | 0.0341 ± 0.1723 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.
| Scores on a scale | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Mean Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 24 - LOCF | 3.14 ± 10.21 | -2.58 ± 10.07 |
| Percentage of participants | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Percentage of Participants Who Were Withdrawn From Study Drug During the First 24 Weeks | 6.7 | 19.4 |
A negative change from baseline indicates improvement, ie, less leakage.
| Disc areas | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham |
|---|---|---|
| Mean Change in Area of Leakage From Baseline at Week 24 - LOCF | -0.4743 ± 0.4839 | 0.2094 ± 0.5088 |
Collected over From the first study drug injection until 30 days after the last study drug injection at the latest up to week 48.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept Injection (Until Week 20) | — | 3/91 (3.3%) | 30/91 (33%) |
| Sham Treatment (Until Week 20) | — | 0/31 (0%) | 8/31 (25.8%) |
| Aflibercept Injection (Until Week 44) | — | 4/91 (4.4%) | 18/91 (19.8%) |
| Sham Treatment Then Aflibercept Injection (Until Week 44) | — | 0/31 (0%) | 8/31 (25.8%) |
| Event | Aflibercept Injection (Until Week 20) | Sham Treatment (Until Week 20) | Aflibercept Injection (Until Week 44) | Sham Treatment Then Aflibercept Injection (Until Week 44) |
|---|---|---|---|---|
| Macular holeEye disorders | 0/91 | 0/31 | 2/91 | 0/31 |
| Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders | 1/91 | 0/31 | 0/91 | 0/31 |
| Choroidal neovascularisationEye disorders | 0/91 | 0/31 | 1/91 | 0/31 |
| Pneumonia moraxellaInfections and infestations | 0/91 | 0/31 | 1/91 | 0/31 |
| Cerebral haemorrhageNervous system disorders | 1/91 | 0/31 | 0/91 | 0/31 |
| DepressionPsychiatric disorders | 1/91 | 0/31 | 0/91 | 0/31 |
| Event | Aflibercept Injection (Until Week 20) | Sham Treatment (Until Week 20) | Aflibercept Injection (Until Week 44) | Sham Treatment Then Aflibercept Injection (Until Week 44) |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 9/91 | 2/31 | 9/91 | 2/31 |
| Posterior capsule opacificationEye disorders | 0/91 | 0/31 | 0/91 | 3/31 |
| Punctate keratitisEye disorders | 4/91 | 3/31 | 5/91 | 3/31 |
| Conjunctival haemorrhageEye disorders | 7/91 | 1/31 | 7/91 | 1/31 |
| Dry eyeEye disorders | 6/91 | 1/31 | 1/91 | 1/31 |
| Eye painEye disorders | 6/91 | 1/31 | 2/91 | 1/31 |
| HeadacheNervous system disorders | 6/91 | 1/31 | 0/91 | 0/31 |
| Herpes zosterInfections and infestations | 0/91 | 2/31 | 0/91 | 0/31 |
| NauseaGastrointestinal disorders | 5/91 | 0/31 | 3/91 | 0/31 |
| Age, Continuous(Years) | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham | Total |
|---|---|---|---|
| Mean | 58.5 ± 13.7 | 57.5 ± 12.1 | 58.2 ± 13.3 |
| Sex: Female, Male(Participants) | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham | Total |
|---|---|---|---|
| Female | 65 | 27 | 92 |
| Male | 25 | 4 | 29 |
| Baseline Best Corrected Visual Acuity (BCVA) letter scores(Letters correctly read) | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham | Total |
|---|---|---|---|
| Mean | 56.4 ± 9.8 | 56.6 ± 8.9 | 56.5 ± 9.5 |
| Baseline Central Retinal Thickness by Optical Coherence Tomography (OCT)(µm) | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham | Total |
|---|---|---|---|
| Mean | 349.7 ± 91.3 | 354.2 ± 107.2 | 350.9 ± 95.2 |
| Baseline intraocular pressure(mm Hg) | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham | Total |
|---|---|---|---|
| Mean | 15.2 ± 2.7 | 15.8 ± 2.8 | 15.4 ± 2.7 |
| Number of participants by category of time since mCNV diagnosis(Participants) | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham | Total |
|---|---|---|---|
| >= 2 months | 17 | 7 | 24 |
| < 2 months | 73 | 24 | 97 |
| Baseline National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total score(scores on a scale) | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham | Total |
|---|---|---|---|
| Mean | 70.47 ± 13.48 | 72.73 ± 15.29 | 71.04 ± 13.94 |
| European questionnaire 5 dimensions (EQ-5D) total score(score on a scale) | Aflibercept Injection First, Then Aflibercept or Sham | Sham Treatment First, Then Aflibercept Injection or Sham | Total |
|---|---|---|---|
| Mean | 0.88 ± 0.18 | 0.88 ± 0.15 | 0.88 ± 0.18 |
5 further baseline measures are reported on the registry.
The record gives a start of Dec 2010, a primary completion of Feb 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept